The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients

Cancer

Volumn 86, Issue 11, 1999, Pages 2238-2245

  Urban, Thierry ^a   Chastang, Claude ^b   Lebas, François Xavier ^c   Duhamel, Jean Paul ^d   Adam, Guy ^e   Darse, Jacqueline ^f   Bréchet, Jeanne Marie ^g   Lebeau, Bernard ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Service de Pneumologie   (France)

^d Service de Pneumologie   (France)

^e CENTRE HOSPITALIER   (France)

^f Hôpital Cochin ^*  (France)

^g HÔTEL DIEU   (France)

Author keywords

Chemotherapy; Cisplatin; Intensive chemotherapy; Randomized clinical trial; Small cell lung carcinoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033432770     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991201)86:11<2238::AID-CNCR10>3.0.CO;2-G     Document Type: Article

References (37)

1. Aisner J, Alberto P, Bitran J, Comis R, Daniels J, Hansen H, et al. Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 1983;67:37-42.
2. Smyth JF. Chemotherapy of small cell lung cancer. Chest 1989;96:61-2.
3. Souhami RL, Law K. Longevity in small cell lung cancer: a report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990;61:584-9.
4. Rosti G, Donadio M, Crino L. Long survivors in small cell lung cancer (SCLC): Italian report on 3245 cases. Proc Am Soc Clin Oncol 1991;10:268.
5. Pignon IP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A metaanalysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992;327:1618-24.
6. Lebeau B, Chastang C, Bréchot JM, Capron F, Dautzenberg B, Delaisements C, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994;74: 38-45.
7. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristin versus cisplatin, and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 1991;83:855-61.
8. Bunn PA, Cullen M, Fukuoka M. Chemotherapy in small cell lung cancer: a consensus report. Lung Cancer 1989;5:127-34.
9. Hansen HH, Dombernowsky P, Hansen M, Hirsch F. Chemotherapy of advanced small cell anaplastic carcinoma superiority of a four-drug combination to a three drug combination. Ann Intern Med 1979;89:177-81.
10. Aisner J, Whitacre MY, Abrams J, Propert K. Doxorubicin, cyclophosphamide, etoposide and platinum, Adriamycin, cyclophosphamide, etoposide for small cell lung cancer. Semin Oncol 1986;13:54-62.
11. Lebeau B, Chastang C, Urban T, Vincent J, Bréchot JM, Lebas FX, et al. A randomized clinical trial comparing concurrent and alternated thoracic irradiation in limited small cell lung cancer. Proc Am Soc Clin Oncol 1996;15:383.
12. World Health Organization. The World Health Organization histological typing of lung tumors. 2nd ed. Am J Clin Pathol 1982;77:123-36.
13. Lebeau B, Chastang C, Jeannin L. Anticoagulants in small cell lung cancer (SCLC): a randomized clinical trial comparing five weeks of heparin at curative dosage vs. five months of low molecular weight heparin at preventive dosage (abstract no. 385). Lung Cancer 1994;11(Suppl 1):101.
14. Lebeau B, Chastang C, Allard P, Migueres J, Boita F, Fichet D. Six vs. twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. Eur Respir J 1992;5:286-90.
15. George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some critical event. J Chron Dis 1974;27:5-24.
16. Aisner J, Whitacre MY, Budman DR, Propert K, Strauss G, Van Echo DA, et al. Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small cell lung cancer. Cancer Chemother Pharmacol 1992;29:435-8.
17. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
19. Hill C, Com-Nougé C, Kramar A. Analyse statistique des données de survie. Paris: Flammarion, 1990.
20. Edmonson JH, Lagakos SW, Selawry OS, Perlia CP, Bennett JM, Muggia FM, et al. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 1976;60:925-32.
21. Hansen HH, Sealy R. Combination chemotherapy of advanced lung cancer. A randomized trial. Cancer 1976;38: 2201-7.
22. Lininger TR, Fleming TR, Eagen RT. Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer. Cancer 1981;48:2147-53.
23. Goldie JH, Coldmann AJ. The genetic origin of drug resistance in neoplasms implications for systemic therapy. Cancer Res 1984;44:3643-53.
24. Hansen HH, Kristjansen PEG. Chemotherapy of small-cell lung cancer. Eur J Cancer 1991;27:342-9.
25. Hansen HH. Management of small-cell cancer of the lung. Lancet 1992;339:846-9.
26. Sculier JP, Paesmans M, Bureau G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small cell lung cancer: a Phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993;11:1858-65.
27. Spiegelman D, Maurer H, Ware JH, Perry MC, Chahinian AP, Comis R, et al. Prognostic factors in small-cell carcinoma of the lung. An analysis of 1521 patients. J Clin Oncol 1989;7: 344-54.
28. Osterlind K, Anderson PK. Prognostic factors in small-cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986;46:4189-94.
29. Osterlind K, Hansen HH, Hansen M, Dombernowsky P, Anderson PK. Long-term disease free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 1986;4:1307-13.
30. Aisner J. Extensive-disease small cell lung cancer: the thrill of victory, the agony of defeat. J Clin Oncol 1996;14:658-65.
31. Hughes WT, Armstrong D, Bodey GP, Anaissie E, Rolston K, Khardori N, et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
32. Bodey GP, Fainstein V, Elting IS, Anaissie EJ, Khardori NM, Joshi JH, et al. Beta-lactam regimens for the febrile neutropenic patient. Cancer 1990;65:9-16.
33. Rolston KV, Berkley P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
34. Lebeau B, Chastang C, Charransol A, Capron F, Lebas FX, Duhamel JP, et al. Risk factors of death due to bone marrow hypoplasia induced by chemotherapy (CT) without CSF in 1350 patients with small cell lung cancer (SCLC). Lung Cancer 1994;11:84.
35. Radford JA, Ryder NDJ, Dodwell D, Anderson H, Thatcher N. Predicting septic complications of chemotherapy: an analysis of 381 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 1993;29: 81-6.
36. Crawford J, Ozer H, Stoller R, Johson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325: 164-70.
37. Trillet-Lenoir V, Green J, Manegold C, Von Powel J, Gatzmeier V, Lebeau B, et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29:319-24.